Minnesota is currently home to 2089 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Nephrotic Syndrome Study Network
NCT01209000
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Register for Updates
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients
NCT06824402
Recruiting
The goal of this clinical trial is to evaluate which biopsy collection method helps to better diagnose rejection and relevant pathologic findings in lung transplant recipients. The main questions it aims to answer are: Does the 1.1 mm cryoprobe or the biopsy forceps provide better quality samples of lung tissue for detecting rejection in transplant recipients? How much tissue is adequate for lung transplant 1.1 mm cryobiopsy samples as compared to biopsy forceps? Which samples received by the... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/17/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lung Transplant Rejection
Register for Updates
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT06596252
Recruiting
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Dr. Falk Investigational Site, Rochester, Minnesota
Conditions: Eosinophilic Esophagitis
Register for Updates
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
NCT06395441
Recruiting
This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Fibrosis Lessens After Metabolic Surgery
NCT06374875
Recruiting
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Register for Updates
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
NCT06374797
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Acute Kidney Injury
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Saint Paul, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908
Recruiting
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Allina Health Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Register for Updates
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
Register for Updates
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773
Recruiting
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Bladder Carcinoma in Situ (CIS)
Register for Updates
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Register for Updates
Graded Exercise Hypoxia Testing
NCT06901284
Recruiting
The purpose of this study is to develop a single, standardized test to determine how individuals tolerate acute hypoxia in a stepwise fashion. We aim to evaluate the association between multiple factors, such as ventilatory compensation, heart rate response, acid-base changes, sex, pulmonary function, etc, which may explain why some individuals tolerate exercise in hypoxia better than others. Identifying these factors of association will inform future pharmacological and non-pharmacological atte... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hypoxia
Register for Updates